Glemanserin: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{Short description|A selective 5-HT2A receptor antagonist}} | |||
{{Drugbox | |||
| verifiedfields = changed | |||
| verifiedrevid = 477002123 | |||
| image = Glemanserin_structure.png | |||
| image_size = 200px | |||
| image_alt = Chemical structure of Glemanserin | |||
}} | |||
'''Glemanserin''' is a chemical compound that acts as a selective antagonist of the [[5-HT2A receptor]], a subtype of the [[serotonin receptor]]. It has been studied for its potential therapeutic effects in various [[psychiatric disorders]], including [[schizophrenia]] and [[anxiety disorders]]. | |||
Glemanserin | ==Pharmacology== | ||
Glemanserin is known for its high affinity and selectivity for the 5-HT2A receptor, which is a [[G protein-coupled receptor]] (GPCR) involved in the modulation of neurotransmission in the [[central nervous system]]. By blocking the action of serotonin at this receptor, glemanserin can alter the activity of neural circuits implicated in mood and perception. | |||
==Mechanism of Action== | |||
The primary mechanism of action of glemanserin is the antagonism of the 5-HT2A receptor. This receptor is widely distributed in the [[brain]], particularly in areas such as the [[prefrontal cortex]], [[hippocampus]], and [[thalamus]]. By inhibiting the receptor, glemanserin can reduce the excitatory effects of serotonin, potentially leading to anxiolytic and antipsychotic effects. | |||
== Clinical | ==Clinical Research== | ||
Research into glemanserin has focused on its potential use in treating psychiatric conditions. Studies have explored its efficacy in reducing symptoms of schizophrenia, particularly those related to [[hallucinations]] and [[delusions]]. Additionally, its role in managing anxiety disorders has been investigated, with some studies suggesting it may help alleviate symptoms of [[generalized anxiety disorder]] and [[panic disorder]]. | |||
Glemanserin is | ==Chemical Structure== | ||
[[File:Glemanserin_structure.png|thumb|right|200px|Chemical structure of Glemanserin]] | |||
Glemanserin is a small molecule with a specific chemical structure that allows it to bind selectively to the 5-HT2A receptor. The structure of glemanserin includes a core aromatic ring system, which is crucial for its receptor binding properties. | |||
== Side Effects == | ==Potential Side Effects== | ||
As with many pharmacological agents, glemanserin may have side effects. Commonly reported side effects include [[drowsiness]], [[dry mouth]], and [[dizziness]]. More serious side effects are rare but can include [[cardiovascular effects]] such as changes in [[blood pressure]] and [[heart rate]]. | |||
==Related Compounds== | |||
Glemanserin is part of a class of compounds known as 5-HT2A receptor antagonists. Other compounds in this class include [[ketanserin]] and [[ritanserin]], which have been studied for similar therapeutic applications. | |||
== | ==Related pages== | ||
* [[Serotonin receptor]] | |||
* [[Antipsychotic]] | |||
* [[Anxiolytic]] | |||
* [[Schizophrenia]] | |||
* [[Anxiety disorder]] | |||
[[Category:5-HT2A antagonists]] | |||
[[Category:Experimental drugs]] | |||
[[Category: | |||
[[Category: | |||
Latest revision as of 11:07, 15 February 2025
A selective 5-HT2A receptor antagonist
| Glemanserin | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Glemanserin is a chemical compound that acts as a selective antagonist of the 5-HT2A receptor, a subtype of the serotonin receptor. It has been studied for its potential therapeutic effects in various psychiatric disorders, including schizophrenia and anxiety disorders.
Pharmacology[edit]
Glemanserin is known for its high affinity and selectivity for the 5-HT2A receptor, which is a G protein-coupled receptor (GPCR) involved in the modulation of neurotransmission in the central nervous system. By blocking the action of serotonin at this receptor, glemanserin can alter the activity of neural circuits implicated in mood and perception.
Mechanism of Action[edit]
The primary mechanism of action of glemanserin is the antagonism of the 5-HT2A receptor. This receptor is widely distributed in the brain, particularly in areas such as the prefrontal cortex, hippocampus, and thalamus. By inhibiting the receptor, glemanserin can reduce the excitatory effects of serotonin, potentially leading to anxiolytic and antipsychotic effects.
Clinical Research[edit]
Research into glemanserin has focused on its potential use in treating psychiatric conditions. Studies have explored its efficacy in reducing symptoms of schizophrenia, particularly those related to hallucinations and delusions. Additionally, its role in managing anxiety disorders has been investigated, with some studies suggesting it may help alleviate symptoms of generalized anxiety disorder and panic disorder.
Chemical Structure[edit]
Glemanserin is a small molecule with a specific chemical structure that allows it to bind selectively to the 5-HT2A receptor. The structure of glemanserin includes a core aromatic ring system, which is crucial for its receptor binding properties.
Potential Side Effects[edit]
As with many pharmacological agents, glemanserin may have side effects. Commonly reported side effects include drowsiness, dry mouth, and dizziness. More serious side effects are rare but can include cardiovascular effects such as changes in blood pressure and heart rate.
Related Compounds[edit]
Glemanserin is part of a class of compounds known as 5-HT2A receptor antagonists. Other compounds in this class include ketanserin and ritanserin, which have been studied for similar therapeutic applications.
